Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery.
Raverdy V, Tavaglione F, Chatelain E, Caiazzo R, Saponaro C, Lassailly G, Verkindt H, Baud G, Marciniak C, Chetboun M, Oukhouya-Daoud N, Gnemmi V, Leteurtre E, Duhamel A, Philippe M, Marot G, Romeo S, Pattou F. Raverdy V, et al. Among authors: saponaro c. Metabolism. 2024 Apr;153:155790. doi: 10.1016/j.metabol.2024.155790. Epub 2024 Jan 12. Metabolism. 2024. PMID: 38219973 Free article.
SGLT2 inhibition and glucagon secretion in humans.
Saponaro C, Pattou F, Bonner C. Saponaro C, et al. Diabetes Metab. 2018 Nov;44(5):383-385. doi: 10.1016/j.diabet.2018.06.005. Epub 2018 Jun 30. Diabetes Metab. 2018. PMID: 30017776 Review.
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions.
Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, Denis RGP, Chao DHM, Rasika S, Staels B, Pattou F, Pfrieger FW, Brodin B, Luquet S, Bonner C, Prevot V. Imbernon M, et al. Among authors: saponaro c. Cell Metab. 2022 Jul 5;34(7):1054-1063.e7. doi: 10.1016/j.cmet.2022.06.002. Epub 2022 Jun 17. Cell Metab. 2022. PMID: 35716660 Free PMC article.
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
Saponaro C, Gmyr V, Thévenet J, Moerman E, Delalleau N, Pasquetti G, Coddeville A, Quenon A, Daoudi M, Hubert T, Vantyghem MC, Bousquet C, Martineau Y, Kerr-Conte J, Staels B, Pattou F, Bonner C. Saponaro C, et al. Cell Rep. 2019 Aug 6;28(6):1447-1454.e4. doi: 10.1016/j.celrep.2019.07.009. Cell Rep. 2019. PMID: 31390560 Free article.
Where to for precision treatment of HNF1A-MODY?
Bonner C, Saponaro C. Bonner C, et al. Among authors: saponaro c. Diabetologia. 2022 Nov;65(11):1825-1829. doi: 10.1007/s00125-022-05696-4. Epub 2022 Apr 12. Diabetologia. 2022. PMID: 35412067 No abstract available.
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.
Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Younes R, Saponaro C, Buzzigoli E, Caviglia GP, Abate ML, Smedile A, Rizzetto M, Cassader M, Gastaldelli A, Bugianesi E. Rosso C, et al. Among authors: saponaro c. Hepatology. 2016 Jan;63(1):107-16. doi: 10.1002/hep.28287. Epub 2015 Dec 8. Hepatology. 2016. PMID: 26473614 Free article.
61 results